Opinion|Videos|September 17, 2024
Management of Oral Toxcities associated with GPRC5D Bispecifics Nail
Author(s)Larysa Sanchez, MD, Samantha Shenoy, NP, MSN
Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are some adverse events (AEs) observed with talquetamab and how are these managed?
- Please discuss management of oral toxicities.
- Please discuss management of skin and nail AEs.
Advertisement
Related to this article
Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5